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1  | INTRODUC TION
Aging is associated with multiple—often chronic—illnesses, with an in‐
creased risk of the prescription of multiple medicines. The use of nu‐
merous medications—generally described as polypharmacy—can lead to 
unfortunate conditions and some medications are known to interact 
with each other.1,2 Elderly patients are more likely to experience poly‐
pharmacy compared to other age groups, as they tend to suffer from 
more therapeutic conditions requiring pharmacotherapy. Polypharmacy 
in elderly individuals poses a significant risk to well‐being; however, it 
is difficult to avoid.3‐5 With this background, we aimed to summarize 
the existing evidence regarding the impact of polypharmacy in elderly 
cancer patients. We also aimed to provide some strategies for clinical 
pharmacists to contribute to the management of such problems.
2  | POLYPHARMACY
With regards to the definition of polypharmacy, there is contention as 
there is no standard meaning for the term. Be that as it may, the term 
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Abstract
The aim of this study was to address the problems associated with polypharmacy in 
elderly cancer patients and to highlight the role of pharmacists in such cases in re‐
source‐limited settings. A narrative review of existing literature was performed to 
summarize the evidence regarding the impact of polypharmacy in elderly cancer pa‐
tients and the pharmaceutical strategies to manage it. This review emphasizes the 
significance of polypharmacy, which is often ignored in real clinical practice. 
Polypharmacy in the elderly cancer population is mainly due to: chemotherapy with 
one or more neoplastic agents for cancer treatment, treatment for adverse drug re‐
actions due to neoplastic agents, the patient's comorbid conditions, or drug interac‐
tions. The role of the clinical pharmacist in specialized oncology hospitals or oncology 
departments of tertiary care hospitals is well established; however, this is not the 
case in many developing countries. A clinical pharmacist can contribute to solving the 
problems associated with polypharmacy by identifying the risks associated with 
polypharmacy and its management in resource‐limited settings. As in many devel‐
oped countries, the involvement of a clinical pharmacist in cancer care for elderly 
patients may play a vital role in the recognition and management of polypharmacy‐
related problems. Further research can be conducted to support this role.
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polypharmacy can be characterized from multiple points of view. As 
indicated by Hajjar et al,6 polypharmacy is characterized as “the use 
of multiple medications and/or the administration of more medica‐
tions than are clinically indicated, representing unnecessary drug 
use.” Polypharmacy comprises of the number of medications taken 
by the patient, the existence of one or more wrong medications in a 
prescription, or an amalgamation of both, which can increase the risk 
for adverse drug events (ADEs), underutilization of medication, and 
repetition of medicine.6 Polypharmacy can be defined as “the use of 
multiple drugs or more than are medically necessary, [and it] is a de‐
veloping concern for senior adults.”7 Because of its relationship with 
antagonistic medication responses and falls, the term polypharmacy 
has negative connotations with a range of adverse events among the 
officially powerless geriatric populace.8
Polypharmacy can be a mild to severe issue for patients of any 
age group, but particularly for elderly patients. For instance, due to 
the existence of various comorbidities in elderly cancer patients, 
drug therapies might be combined; furthermore, the expanded ac‐
cessibility of over‐the‐counter, herbal, and complementary/alterna‐
tive medicines (which patients often fail to declare to their specialist, 
doctor, or pharmacist) can contribute to polypharmacy. These pop‐
ulations remain at high risk for ADEs linked with polypharmacy and 
drug‐drug interactions (DDIs). Elderly patients undergo many phys‐
iologic changes that may modify the different pharmacokinetics pa‐
rameters, such as absorption, first‐pass metabolism, protein binding, 
distribution, metabolism, and eliminations of the drugs. Molecular 
and cellular fluctuations may modify the pharmacodynamics of me‐
tabolism of the drug variations and may alter the effect of a drug on 
its target site and the narrow therapeutic windows related with che‐
motherapeutic agents due to the drugs that are given.9,10 Together 
with the alterations in pharmacokinetic and pharmacodynamic vari‐
ables, the risk in elderly patients is increased due to adverse drug 
reactions (ADRs).
3  | POLYPHARMACY IN ELDERLY C ANCER 
PATIENTS
Among elderly cancer patients, polypharmacy has a noteworthy 
consequence and its incidence is increasing. Nevertheless, its pre‐
dominance and impacts in disease patients are not well defined, 
particularly in end‐of‐life scenes.11 Globally, numerous elderly can‐
cer patients, many with comorbidities, are being treated with at 
least one or more drugs in oncology hospitals or clinics. In the man‐
agement of most cancers, chemotherapy in combination with other 
treatments is more common than single chemotherapy agents. The 
inception of chemotherapy with at least one cytotoxic or targeted 
agent as well as drugs for the management of growth manifesta‐
tions or the harmful impacts identified with treatment can result in 
polypharmacy.12
Prescribing the drug or chemotherapeutic agents is one of 
the foremost challenges in treating elderly cancer patients; fur‐
thermore, it is not simple. Cancers patients are at great risk of 
medication‐connected events as they are usually prescribed an 
extensive number of medicines, both for the disease itself and for 
supportive care.13
The treatment of cancer involves multiple medications and in‐
cludes the unfavorable impacts/reactions of the cytotoxic treat‐
ments.14 Usage of multiple medicines is an important factor for 
treating the health conditions of elderly people; however, compli‐
cations can arise from antineoplastic therapy, which might influence 
the consequences of cancer treatment.1
The practice of many medicines can prompt additional drugs to 
the medication regimen, as different medications are prescribed to 
respond to the problems of former medicines, which is especially 
valid in the case of cytotoxic chemotherapy for the management of 
malignancy. There are numerous ADRs, ranging from mild nausea to 
myelosuppression, because of anticancer agents, which may prompt 
polypharmacy.14
3.1 | Prevalence of polypharmacy in elderly 
cancer patients
The reported prevalence of polypharmacy in the elderly population 
varies substantially, ranging from 10% to 96%.15 Due to changes in the 
pharmacokinetic profile associated with aging, elderly patients have 
varied pharmacodynamic responses to medications. The comorbid 
condition due to aging leads to a higher prevalence of polypharmacy 
in the elderly population than that in younger patients.16 Therefore 
this group is more likely to suffer from ADEs or decreased therapeu‐
tic/beneficial effects of the medications. Elderly cancer patients are 
often exposed to chemotherapy and radiotherapy and these chem‐
otherapeutic agents may lead to acute or long‐term toxicity, which 
might require other supportive medications. This might result in drug 
interactions and increased drug burden.17 Balducci et al1 examined 
numerous studies in elderly cancer patients that showed age as a risk 
factor for polypharmacy, which may interrupt the consequence of the 
cancer treatment. Similarly, Jørgensen et al18 reported that 35% of el‐
derly patients diagnosed with breast, lung, colon, rectal, prostate, or 
ovarian cancer were each taking more than five drugs between 1996 
and 2006. They found that the prevalence of polypharmacy increased 
with age (39% of 80‐90‐year‐old patients and 41% of 90‐91‐year‐old 
patients). Polypharmacy was more common among older cancer pa‐
tients compared to younger cancer patients and those in the same age 
group without cancer. Surprisingly, it was also found that an increase 
in several prescribed drugs was initiated before 6 months of manifes‐
tations of malignant growth, demonstrating the increase in trend of 
prescription drugs during such period.
A study conducted in ambulatory cancer patients in Canada sug‐
gested that in newly diagnosed cancer patients aged 60 years and 
above, polypharmacy was assessed as taking an average of five med‐
ications at the time of diagnosis.13 A Scottish study assessed com‐
munity‐dispensed prescription and adverse event data from 1995 to 
2010 and revealed that the number of dispensed medications was 
a significant forecaster for potentially serious DDIs.19 Nobili et al20 
also supported previous findings and concluded that the elderly 
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population constitutes the largest group of people highly susceptible 
to developing DDIs.
Besides the aforementioned studies, there is other evidence that 
supports the higher prevalence of polypharmacy in the elderly popu‐
lation. For example, a retrospective cross‐sectional study conducted 
by Goh et al17 evaluated the types and incidence of drug‐related prob‐
lems among elderly cancer patients and showed the non‐adherence, 
underprescribing, and ADEs. Drug‐related problems were identified 
in 77.6% of elderly cancer patients (approximately one incidence of 
three drug‐related problems per patient). Polypharmacy leading to 
drug‐related problems is prevalent in elderly cancer patients receiving 
outpatient intravenous chemotherapy.17 Prithviraj et al21 conducted a 
cross‐sectional study showing a high prevalence of polypharmacy and 
inappropriate medication in newly diagnosed elderly cancer patients. 
Another prospective and observational study—by Flood et al22 showed 
that polypharmacy was common in elderly cancer patients during hos‐
pitalization in an oncology‐acute care unit for the elderly.
Thus, elderly cancer patients have a higher risk of polypharmacy 
than patients of the same age without cancer.
3.2 | Polypharmacy and association with outcomes 
in geriatric oncology
Polypharmacy is associated with a major problem: the risk of hos‐
pitalization and death among elderly patients with or without can‐
cer.23-27 The review study conducted in 2016 associated multiple 
risks factors for adverse outcomes in geriatric oncology as a result 
of polypharmacy.15 In an oncology setting, polypharmacy with in‐
appropriate medications may contribute to: the patient's worsened 
condition, frailty syndrome, poor physical function, poor survival, 
and a higher number of comorbidities.28‐30 Some studies have aimed 
to associate polypharmacy and its outcomes in geriatric oncology; 
for example, in 2014, Kim et al31 considered a group of patients aged 
65 years and over who underwent a comprehensive geriatric assess‐
ment (CGA) before palliative first‐line chemotherapy (various cancer 
sites were involved). Out of 98 patients, 40% of patients met the 
criteria for polypharmacy. The result was observed to have no con‐
nection with early termination of palliative chemotherapy.
The current evidence advocates that with an increase in the 
number of medications used in geriatric cancer patients, there is a 
high risk of chemotherapy‐induced toxicity and adverse physiologi‐
cal functions. Some of the prominent ADRs associated with chemo‐
therapies are defective blood counts, immunosuppression, nausea, 
vomiting, hair loss, renal toxicity, and hepatotoxicity. Lastly, the in‐
tervention and screening of polypharmacy in regular clinical practice 
may require precise studies to scrutinize the impact of polyphar‐
macy and its outcomes in geriatric cancer patients.15
3.3 | Interventions for polypharmacy in geriatric 
assessment studies
To some extent, polypharmacy has been aligned with evalua‐
tion studies in geriatric oncology settings. However, there is no 
assessment of polypharmacy as a factor to predispose adverse re‐
actions; furthermore, interventions for polypharmacy are uncertain. 
There is an urgent need for consistent interventions to manage poly‐
pharmacy in geriatric oncology practice.15
In a prospective study of elderly cancer patients aged 70 years 
or more, geriatricians proposed a change in prescribed medications 
(mostly in switching chemotherapy to supportive care) in more than 
20% of patients based on CGA results; however, the proposed medi‐
cation intervention and its benefits were not reported.32
In contrast, a prospective cohort study conducted by Kalsi et al33 
showed an association between geriatrician‐led CGA interventions 
and improved chemotherapy tolerance in geriatric patients aged 
70 or more during chemotherapy. The intervention was applied to 
unnecessary medications, such as adjustment of antihypertensive 
medications in over‐ or undertreated patients wherein 19% of un‐
dertreated patients benefited.
Aparicio et al34 conducted a pilot study to assess the viability of 
mini geriatric assessment (MGA) done by a gastroenterologist, which 
showed the adaptation of non‐oncological therapy and social care 
due to MGA in 72% and 38% of patients, respectively. Yet, there 
was no difference in strategy, which suggested that MGA could help 
gastroenterologists for adaptation of treatment of cancer.
An intervention study was done by Sokol et al10 in which oncol‐
ogists were required to change their prescriptions based on possible 
drug interactions; however, the physicians did not edit prescrip‐
tions unrelated to potential drug interactions. The study concluded 
that physicians should consider possible outcomes in association 
with polypharmacy and chronic use data. Incentives should be pro‐
vided to physicians for optimization of safe and effective oncologic 
therapeutics.
A 2012 interventional study by Horgan et al35 assessing CGA 
provides recommendations on modification of medication for geri‐
atric oncology patients aged above 70 years. This intervention led 
to the identification of previously unidentified medical problems in 
70% of patients.
Corcoran et al36 suggested reducing the risks associated with 
polypharmacy by: educating patients and physicians, drug monitor‐
ing, and intervention. Additionally, investigations into the pharmaco‐
kinetic parameters of chemotherapeutic agents provide information 
on: possible drug interactions and adverse outcomes, how to decide 
on toxicity levels, and how to prevent the pharmacological responses 
of drug interactions.
Finally, an intervention study involving a multidisciplinary team, 
including clinical pharmacists, enrolled high‐risk geriatric patients 
with polypharmacy and showed an effective reduction of unneces‐
sary medications resulting in improved patient health outcomes.7
4  | RISKS AND PROBLEMS A SSOCIATED 
WITH POLYPHARMACY
There are various unfavorable results related to polypharmacy, 
which is regrettable as it is often unavoidable. These include ADRs, 
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drug interactions, prolonged hospitalization or increased hospital 
stay, and an increase in the cost of health care.
4.1 | Adverse drug reactions
The burden of polypharmacy increases the greater cost of health care. 
It is also connected to elevated risk of ADEs in elderly patients due 
to: the greater possibility of DDIs, medication adherence, the vulner‐
ability of the elderly populace to side‐effects of medications, and 
physical changes identified with aging that trigger difficulties in taking 
medicines as proposed.37,38 Runciman et al39 affirmed that ADEs are 
accountable for more than 30% of unexpected hospital admissions in 
people aged 75 years and above in Australian health care settings.
4.2 | Drug interactions
The frequency of drug interactions in elderly patients is not well docu‐
mented. Senior patients are at greatest risk of having drug-related in‐
teractions and various kinds of drug interactions can happen, including 
drug‐drug, drug‐disease, drug‐food, drug‐alcohol, drug‐herbal‐prod‐
ucts, and drug‐nutritional‐status interaction. The variables, including 
age‐related physiologic alterations in pharmacokinetics and pharma‐
codyanmics, infirmity, inter‐individual variability, decreased homoeo‐
static mechanisms of the human body, and psychosocial concerns 
(which are almost universal among patients who have progressive life‐
threatening diseases), should be considered when drug interactions are 
evaluated.40 One of the most important challenges in elderly patients 
with cancer is a drug interaction that is inescapable.41
Polypharmacy and drug interactions have been recognized as the 
most hazardous factors for ADR, which is one of the most common 
outcomes.42 This may be the reason for multiple visits to the emer‐
gency department.43 The threat of polypharmacy plus DDI is greater 
in elderly individuals, who regularly experience the ill effects of a 
variety of therapeutic conditions and are thus prescribed multiple 
medications, several of which are connected with each other to de‐
liver undesirable impacts. Ruiter et al44 found that ADRs and DDIs 
increased the risk of hospitalization by fourfold in patients aged 
75 or more, compared to those aged 55 to 74 years. Alkan et al45 
found that out of 445 elderly cancer patients, nearly one‐third were 
exposed to potentially inappropriate medications and drug interac‐
tions that were very severe. In this study, the investigators found 
that polypharmacy (with more than five drugs), inpatient status, and 
diagnosis of lung cancer were connected with severe drug interac‐
tions. This study, which was carried out in Turkey, suggests that cli‐
nicians should be more restrained when prescribing and preparing 
drugs for elderly patients. Girre et al41 conducted a study in France 
among 105 patients and found that almost half of the interactions 
were moderate.
4.3 | Increased health care cost
Another possible issue that accompanies polypharmacy is increased 
health care cost, which may be direct or indirect. An association 
among polypharmacy, DDIs, ADRs, and repeated hospital admission 
has been demonstrated by researchers.46‐48 ADEs increase health 
care costs by increasing hospital admissions, or as a result of unpre‐
dicted drug interaction,14,49 along with increased visits to the emer‐
gency department and clinics.50
Polypharmacy is associated with increased cost,1 increasing 
medical expenses for the patient and the health care institution. 
Increased health care costs include the price of unsuitable or iden‐
tical medications, additional medicines for treating newly induced 
symptoms, laboratory costs, and supplementary patient monitoring 
that may be obligatory.12
In a Swedish study, Hovstadius et al51 describe increases in pre‐
scription medication spending of 6.2% and 7.3% for patients taking 
five or more and 10 or more medications, respectively. Shrestha 
et al14 also discuss the financial burden of patients due to ADRs 
and chemotherapy where more ADRs were seen in patients aged 
more than 60 years. In a retrospective cohort study, Akazawa et al52 
showed an association among polypharmacy, increased risk of taking 
possibly unsuitable medicines, and increased hospital admissions, 
leading to increments in medical costs of approximately 30%.52
5  | MANAGEMENT OF POLYPHARMACY 
BY CLINIC AL PHARMACISTS IN ELDERLY 
C ANCER PATIENTS
Polypharmacy is a problem that requires a rational and organized 
method. Incorporating clinical pharmacy services into the multidiscipli‐
nary oncology team can play a crucial role in the identification of risks 
accompanying polypharmacy and management of polypharmacy.53 
There are various strategies for managing polypharmacy in elderly can‐
cer patients, which can also be applicable to other chronic diseases.
5.1 | Taking an appropriate medication history
Evaluating the relevance of a patient's present drug therapy and 
guidance to forthcoming treatment selections can be obtained from 
an appropriate medication history. This can be obtained by close 
teamwork among health professionals (i.e., patients, doctors, nurses, 
and clinical pharmacists), in cooperation with patients. Existing 
procedures intended for documenting drug histories have been 
identified as insufficient, needing improvement, and in some cases 
actually hazardous.54 Health professionals should consolidate their 
medical records and keep them up to date. A thorough medication 
history includes an interview with questions about: the currently 
prescribed drugs; doses; routes of administration; frequencies; 
treatment duration; other medications (e.g., over‐the‐counter, herbal 
remedies, complementary/alternative medicines); assessment of 
drug containers or lists, or both; and communication with commu‐
nity pharmacies or specific doctors. Additionally, other information 
on the history from previous medical reports can be obtained, such 
as earlier prescriptions, previous drug interactions, the aforemen‐
tioned ADRs, and previous hypersensitivity reactions.55 One of the 
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most important responsibilities of clinical pharmacists is to obtain 
accurate medication histories with the above‐described methods to 
confirm that the patient's present and forthcoming therapy is harm‐
less and effective.
5.2 | Medication reconciliation and 
medication review
According to St Peter,56 individual procedures are required to avoid 
and resolve medication‐related complications and subsequently to 
reduce polypharmacy. These include parameters such as medica‐
tion reconciliation, medication review, and ongoing patient‐centered 
medication therapy management.56 A multidisciplinary approach 
involving clinical pharmacists in the medical oncology group can ef‐
fectively manage polypharmacy in elderly cancer patients.
Medication reconciliation and medication review are both im‐
perative tools for pharmaceutical care. The two terms are different 
and require definition. Medication reconciliation is the straightfor‐
ward management of drugs,57 that is, the method of building a list 
of correct medications.58 Medication reconciliation is preliminary to 
medication review.
A critical involvement for addressing polypharmacy is a sys‐
tematic and detailed medication review to evaluate whether the 
patient has obtained therapeutic advantage from their medication, 
whether there are continuing medical needs, and whether risks and 
side‐effects are balanced by probable pros.59 The patient's medica‐
tion regimen should be assessed for safety and correctness from the 
perspective of the specific patient's multiple morbid illnesses, health 
literacy, and issues of sociodemographics. Advanced clinical drug 
therapy expertise is necessary for medication review and it is well 
recognized that pharmacists own these clinical skill sets.60
Medication reconciliation and medication review will potentially 
involve the prescription and deprescription of drugs. Similar decent 
practices and standards ought to be connected when medical treat‐
ment is started and when it is discontinued.61 In the global scenario 
of the health care system, deprescribing is an impartially innovative 
theory, which is the way toward decreasing or halting medications, 
aimed at minimizing multiple uses of drugs and improving health out‐
comes for patients.
5.3 | Multidisciplinary approach
In most cases, polypharmacy can be managed with a multidiscipli‐
nary approach. The study by Holland conducted at an Irish teach‐
ing hospital demonstrates how interdisciplinary teamwork between 
the clinical pharmacist and doctor can develop the comprehensive‐
ness and accurateness of discharge medicines through the estab‐
lishment of a discharge medication reconciliation service, which is 
commanded by the pharmacist.57 Shrestha et al53 also stated that 
the clinical pharmacist can act as a bridge between the medical on‐
cologist and the patient in an oncology setting by providing clinical 
pharmacy services. These services, such as discharge medication 
reconciliation, can be best provided by the clinical pharmacist.
5.4 | Patient‐centered medication therapy
The service given by the clinical pharmacist is patient‐centered 
medication therapy management, which is a developing treatment 
plan that concentrates on each intention associated with a patient's 
medication. Recently, medication therapy management has been 
extended as an important initiative, largely due to the need to en‐
hance patients’ medication treatment.62 Most prolonged disease 
conditions, such as cancer, require that patients persist in treatment 
indefinitely, even when asymptomatic, in order to meet therapeutic 
objectives. For the improvement of patients’ health‐related results, 
certain pharmacist‐managed medication therapy programs should 
be maintained.63 This will also help to lower the health care cost of 
the patients.
This is an era of information technology and most hospitals are 
very much linked to this technology, which can enhance the care of 
patients. Online computer software for checking DDIs may diminish 
DDIs. According to the Beers Criteria record, elderly patients should 
be made aware of the possibility that the wrong medication might 
be administered. Regulatory authorities should focus on the distri‐
bution of appropriate medications, such as prescriptions for elderly 
patients, and also support safer alternatives.64
5.5 | Pharmacovigilance center
When it comes to the treatment of cancer patients of any age 
group, ADRs are being documented universally as one of the 
unavoidable constituents of management. ADRs are normal and 
expectable. Once the ADRs are identified, ADR alert stickers or 
notes mentioning ADRs can be placed in the patient's medical 
file. This will help in future and alert the concerned physicians.65 
Additionally, the information should be circulated to the patients 
and related doctors.
5.6 | Drug information center
The drug information center can play a vital role for elderly cancer 
patients in providing information on polypharmacy and ADEs. It can 
also help in the management of polypharmacy. The pharmacist can 
provide the information to elderly patients on different categories, 
such as general information of their diseases and medications, how 
the prescribed medicine works or what it does to the body, possi‐
ble side‐effects and interactions, and duration of the treatments. 
Elderly patients need information on drugs that are dispensed to 
them or prescribed.
5.7 | Educational intervention and awareness of 
polypharmacy
Educational intervention and awareness can shape patients’ at‐
titudes toward polypharmacy. Numerous elderly patients strug‐
gle to deal with their issues in health care. Limited health literacy 
exaggerates such struggles and creates a greater diversity of 
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adverse health activities and consequences for elderly patients. 
The effect of a lack of health literacy on the lives of the elderly 
populace requires greater consideration and understanding from 
community services practice.66 An elderly populace with little 
health literacy is at increased risk of nonadherence, unintentional 
medication experience, and adverse events. Whittaker et al67 rec‐
ommend educational involvement that can build familiarity with 
poison inhibition means and medication safety strategies in older 
adults with low well‐being proficiency. Numerous approaches to 
educational intervention and awareness among patients regarding 
polypharmacy can be used in elderly patients, such as audiovisual 
activities, presentations, and brochures in understandable or local 
languages. Raising physicians’ awareness and ventures to support 
higher experts with respect to polypharmacy and the noxious ef‐
fects of drug interactions may result in healthier outcomes for el‐
derly patients.
6  | CONCLUSION
This review has successfully discussed the challenges associated 
with polypharmacy in elderly cancer patients and the ways in which 
pharmacists can contribute to managing such problems in low‐ and 
middle‐income settings. Polypharmacy in elderly cancer patients is 
one of the most important and growing public health issues; it is a 
grave concern to those who are associated with the management 
of cancer, such as medical oncologists and other clinicians, as poly‐
pharmacy is also related to negative health outcomes. The clinical 
pharmacist has a major role to play in selecting the best interven‐
tions needed to enhance suitable polypharmacy and consequently 
managing problems associated with polypharmacy properly to ac‐
complish better clinical results for patients.
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